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	 A	 series	 of	 new	 thiazolidin‐4‐ones	 have	 been	 synthesized	 by	 the	 reaction	 of	 3‐acetylindole
with	thiourea	to	yield	2‐amino‐arylthiazole	(1)	which,	reacted	with	2‐chloroacetyl	chloride	to
produce	 2‐chloroacetamido‐4‐arylthiazoles	 (2).	 The	 later	 was	 treated	 with	 potassium
thiocyanate	 to	 afford	 the	 related	 2‐amino‐3‐(4‐arylthiazol‐2‐yl)	 thiazolidin‐4‐ones	 (3).
Condensation	of	compounds	1	and	3	with	different	aromatic	aldehydes	give	Schiff’s	bases	(4a‐
c)	 and	 (5a‐c)	 reaction	 of	 compound	 5a‐c	 with	 thioglycollic	 acids	 furnishes	 the	 target
thiazolidin‐4‐one	molecules	(6a‐c).	Further,	condensation	of	compound	6a	with	benzaldehyde
affords	 benzylidenethiazolo	 derivative	 (7)	 which	 on	 refluxing	 with	 malononitrile,
acetylacetone	 afforded	 thiazolopyridine	 derivatives	 (8,9).	 Structure	 elucidation	 of	 the
products	 has	 been	 accomplished	 on	 the	 basis	 of	 elemental	 analysis,	 IR,	 1H	 NMR	 data.
Compound	3exhibited	the	most	potent	antibacterial	and	anticancer	activity.	
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1.	Introduction	
	
Thiazolidinones	 are	 derivatives	 of	 thiazolidine	 and	 they	
also	constitute	an	important	group	of	heterocyclic	compounds	
[1].	 Thiazolidin‐4‐one	 derivatives	 exhibit	 various	 biological	
activities	 such	 as	 anti‐microbial	 [2],	 anti‐inflammatory	 [3,4],	
antihistaminic	 [5],	 anti‐hypertensive,	 analgesic	 [6]	 and	 anti‐
bacterial	activities	[7‐9].	
Thiazolidinones,	with	a	carbonyl	group	in	position	2,	4‐	or	
just	 4‐,	 have	 been	 extensively	 studied	 [10,11]	 and	 literature	
surveys	 showed	 that	 thiazolidin‐4‐ones	 are	 important	
compounds	 due	 to	 their	 broad	 range	 of	 biological	 activities	
[12‐18].	 2‐Substituted	 4‐thiazolidinones	 derivatives	 exhibit	
unusually	 high	 activity	 against	 mycobacterium	 tuberculosis	
when	 tested	 in	 vitro	 [19].	 Overviews	 of	 their	 synthesis,	
properties,	 reactions	 and	 applications	 have	 been	 published	
[10,11].	
Indoles	 have	 been	 reported	 to	 possess	 a	 wide	 variety	 of	
biological	 activities	 like	 anti‐inflammatory	 [20],	 anticancer	
[21],	 antifungal	 [22]	 and	 were	 used	 in	 the	 treatment	 of	
gastrointestinal,	 cardiovascular	 and	 central	 nervous	 system	
(CNS)	 disorders,	 HIV‐1	 integrase	 inhibitors	 for	 antitumor	
activity,	 inhibitors	 of	 hepatitis,	 as	 antibacterial	 and	 as	 anti‐
malarial	 agents	 [23‐28].	 Therefore,	 the	 aim	 of	 the	 present	
work	 was	 to	 prepare	 thiazolidin‐4‐one‐derivatives	 using	 3‐
acetylindol	 in	 order	 to	 find	 out	 new	 biologically	 active	
compounds.	
	
2.	Experimental	
	
2.1.	Instrumentation	
	
All	 melting	 points	 are	 uncorrected	 and	were	 determined	
on	 GallenKamp	 electric	 melting	 point	 apparatus.	 IR	 spectra	
(KBr	 discs)	 were	 recorded	 on	 of	 FT/IR‐400	 spectrophoto‐
meter	 (Perkin	 Elmer).	 1HNMR	 spectra	 were	 recorded	 on	
ovarian	 300	MHz	 (DMSO‐d6)	 solutions.	 Chemical	 shifts	 were	
reported	 as	 δ	 values	 relative	 to	 tetramethylsilan	 (TMS)	 as	
internal	 reference.	 The	 analyses	 were	 carried	 out	 at	 Micro‐
Analytical	Center,	Cairo	University.	
	
2.2.	Synthesis	of	4‐(1H‐indol‐3‐yl)	thiazol‐2‐amine	(1)	
	
3‐Acetylindole	(0.05	mole)	and	thiourea	(0.05	mole)	were	
taken	in	round	bottom	flask	and	dissolved	in	propanol	(35	mL)	
and	 refluxed	 for	 2	 h.	 The	 solid	 obtained	was	 triturated	with	
ethanol	to	remove	unreacted	acetylindole.	To	this	pyridine	(5	
mL)	was	added	continued	refluxed	for	5	h.	
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Scheme	2
	
	
The	reaction	completion	was	monitored	by	TLC.	The	solid	
separated	is	filtered	recrystallized	from	ethanol,	1	(Scheme	1).	
Color:	Pale	yellow.	Yield:	69%.	M.p.:	158‐160	°C.	FT‐IR	(KBr,	,	
cm‐1):	3340	(N‐H),	3012	(Ar‐CH),	1582	(C=N),	1457	(C=C).	1H	
NMR	(300	MHz,	DMSO‐d6,	 δ,	ppm):	4.32	(s,	2H,	NH2),	7.08	(s,	
1H,	 thiazole‐H),	 7.10‐7.60	 (m,	 5H,	 Ar‐H),	 14.01	 (s,	 1H,	 NH).	
Anal.	calcd.	for	C11H9N3S:	C,	61.37;	H,	4.21;	N,	19.52.	Found:	C,	
61.31;	H,	4.20;	N,	19.49%.	
	
2.3.	Synthesis	of	N‐(4‐(1H‐indol‐3‐yl)thiazol‐2‐yl)‐2‐chloro	
acetamide	(2)	
	
In	conical	flask,	0.01	mole	of	2‐amino‐4‐aryl	thiazole	(1)	in	
25	 mL	 benzene	 was	 stirred	 for	 30	 min	 in	 ice‐bath	 till	 the	
temperature	 becomes	 below	 0‐5	 °C	 then	 add	 0.01	 mole	
chloroacetyle	 chloride	was	 add	drop	 by	 drop	 in	 conical	 flask	
within	 2h.	 After	 complete	 addition	 the	 reaction	mixture	was	
refluxed	 it	 for2h	 in	 water	 bath	 then	 the	 solvent	 was	
evaporates.	 The	 product	 that	 separated	was	 recrystallization	
from	ethanol	(Scheme	2).	Color:	Pale	yellow.	Yield:	82%.	M.p.:	
145‐147	C.	FT‐IR	(KBr,	,	cm‐1):	3160	(NH),	3012	(Ar‐H),1633	
(C=O).	 1H	 NMR	 (300	 MHz,	 DMSO‐d6,	 δ,	 ppm):	 4.22	 (s,	 2H,	
COCH2),	7.14‐7.55	(m,	6H,	Ar‐H),	14.00	(s,	1H,	NH).	Anal.	calcd.	
for	C13H10ClN3OS:	C,	53.52;	H,	3.45;	N,	14.40.	Found:	C,	53.50;	
H,	3.41;	N,	14.39%.	
	
2.4.	Synthesis	of	3‐(4‐(1H‐indol‐3‐yl)	thiazol‐2‐yl)‐2‐imino	
thiazolidin‐4‐one	(3)	
	
A	mixture	of	2‐chloro	acetamido‐4‐aryl	 thiazole	 (2)	 (0.03	
mole),	KSCN	(0.06	mole)	in	dry	acetone	(100	mL)	was	refluxed	
for	3	h.	The	 reaction	mixture	was	kept	 for	 evaporated	under	
vacuum	to	obtain	crude	product.	The	residue	was	stirred	with	
water.	 The	 solid	 product	 was	 filtered,	 washed	 with	 water,	
dried	and	 recrystallized	with	ethanol	 (Scheme	2).	Color:	Pale	
brown.	 	 Yield:	 93%.	 M.p.:	 162‐164	 °C.	 FT‐IR	 (KBr,	 ,	 cm‐1):	
3497	(=NH),	3197	(Ar‐H),	1671	(C=O),	1602	(C=N),	705	(C‐S).	
1H	NMR	(300	MHz,	DMSO‐d6,	δ,	ppm):	3.80	(s,	1H,	=NH),	4.10	
(s,	2H,	CH2),	7.12‐8.40	 (m,	6H,	Ar‐H),	11.9	 (bs,	1H,	NH).	Anal.	
calcd.	 for	 C14H10N4OS2:	 C,	 53.49;	 H,	 3.21;	 N,	 17.82.	 Found:	 C,	
53.45;	H,	3.19;	N,	17.80%.	
	
2.5.	General	procedure	for	preparation	3‐(4‐(1‐indol‐3‐yl)	
thiazol‐2‐yl)‐5‐benzylidene‐2‐iminothiazolidine‐4‐one	(4a‐
c)	
	
A	mixture	 iminothiazolidin‐4‐one	 (3)	 (1	mmol),	 aldehyde	
and	 sodium	 acetate	 (1.5	 mmol)	 in	 glacial	 acetic	 acid	 was	
refluxed	 for	 2	 to	 4	 h.	 Till	 completion	 of	 the	 reaction	 (TLC	
check),	 the	 reaction	mixture	was	 poured	 onto	 ice‐cold	water	
the	 solid	 thus	 separated	 was	 filtered	 and	 the	 crude	 product	
was	 recrystallized	 using	 absolute	 ethanol	 to	 get	 compounds	
4a‐c	(Scheme	2).	
3‐(4‐(1H‐Indol‐3‐yl)	thiazol‐2‐yl)‐5‐benzylidene‐2‐iminothia	
zolidin‐4‐one	(4a):	Color:	Brown.	Yield:	94%.	M.p.:	220‐223	°C.	
FT‐IR	 (KBr,	 ,	 cm‐1):	 3488	 (NH),	 1700	 (C=O),	 1640	 (C=CH‐),	
1558	(C=N).	1H	NMR	(300	MHz,	DMSO‐d6,	δ,	ppm):	3.9	(s,	1H,	
=NH),	 7.24‐7.37	 (d,	 1H,	 ‐C=CH),	 7.38‐8.19	 (m,	 11H,	 Ar‐H),	
10.16	 (br,	 1H,	 exchangeable	 with	 D2O).	 Anal.	 calcd.	 for	
C21H14N4OS2:	 C,	 62.67;	 H,	 3.51;	 N,	 13.92.	 Found:	 C,	 62.64;	 H,	
3.42;	N,	13.80%.	
3‐(4‐(1H‐Indol‐3‐yl)thiazol‐2‐yl)‐2‐imino‐5‐(4‐methoxy	
benzylidene)thiazolidin‐4‐one	 (4b):	 Color:	 Brown.	 Yield:	 96%.	
M.p.:	210‐212	°C.	FT‐IR	(KBr,	,	cm‐1):	3497	(NH),	1670	(C=O),	
1660	 (‐C=CH‐),	 1570	 (C=N).	 1H	 NMR	 (300	MHz,	 DMSO‐d6,	 δ,	
ppm):	3.8	(s,	3H,	‐CH3),	7.24‐7.27	(d,	1H,	‐C=CH‐),	7.38‐8.41	(m,	
10H,	Ar‐H),	13.90	(s,	1H,	NH).	
3‐(4‐(1H‐indol‐3‐yl)thiazol‐2‐yl)‐5‐(4‐chlorobenzylidene)‐2‐
iminothiazolidin‐4‐one	 (4c):	 Color:	 Pale	 yellow.	 Yield:	 94%.	
M.p.:	200‐204	°C.	FT‐IR	(KBr,	,	cm‐1):	3460	(NH),	1680	(C=O),	
1560	 (‐C=CH‐).	 1H	NMR	 (300	MHz,	DMSO‐d6,	 δ,	 ppm):	 3.9	 (s,	
1H,	=NH),	7.24‐7.37	(d,	1H,	‐C=CH‐),	7.38‐8.41	(m,	10H,	Ar‐H),	
14.02	(s,	1H,	NH).	
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2.6.	General	procedure	for	the	preparation	of	N‐(substitute	
benzylidene)‐4‐(1H‐indol‐3‐yl)	thiazol‐2‐amine	(5a‐c)	
	
To	 an	 equimolar	 methanolic	 solution	 of	 2‐amino‐4‐aryl	
thiazole	 (0.1	mol)	 and	 substituted	 benzaldehyde	 (0.1	mol),	 a	
few	drops	of	glacial	acetic	acid	were	added.	The	mixture	was	
then	refluxed	on	water	bath	5‐6	h.	It	was	then	allowed	to	cool,	
poured	 into	 crushed	 ice	 and	 recrystallized	 from	 methanol	
(Scheme	3).	
N‐(Benzylidene)‐4‐(1H‐indol‐3‐yl)	 thiazol‐2‐amine	 (5a):	
Color:	Yellow.	Yield:	82%.	M.p.:	166‐168	°C.	FT‐IR	(KBr,	,	cm‐
1):	3400	(N‐H),	1620	(‐N=CH‐).	1H	NMR	(300	MHz,	DMSO‐d6,	δ,	
ppm):	7.0‐7.6	 (m,	11H,	Ar‐H),	8.1	 (s,	1H,	 ‐N=CH),	10.1	 (s,	 1H,	
NH).	Anal.	 calcd.	 for	C18H13N3S	 (303.08):	 C,	 71.26;	H,	4.32;	N,	
13.85.	Found:	C,	71.22;	H,	4.31;	N,	13.82%.	
N‐(4‐Chlorobenzylidene)‐4‐(1H‐indol‐3‐yl)thiazol‐2‐amine	
(5b):	 Color:	 Pale	 yellow.	 Yield:	 85%.	M.p.:	 160‐165	 °C.	 FT‐IR	
(KBr,	,	 cm‐1):	 3310	 (N‐H),	 1600	 (‐N=H).	 1H	NMR	 (300	MHz,	
DMSO‐d6,	 δ,	 ppm):	 7.12‐7.68	 (m,	 10H,	 Ar‐H),	 8.20	 (s,	 1H,	 ‐
N=CH),	10.10	(s,	1H,	NH).	Anal.	calcd.	for	C18H12ClN3S:	C,	64.00;	
H,	3.58;	N,12.44.	Found:	C,	64.12;	H,	3.52;	N,	12.39%.	
N‐(4‐Methoxybenzylidene)‐4‐(1H‐indol‐3‐yl)thiazol‐2‐amin	
(5c):	Color:	Yellow.	Yield:	84%.	M.p.:	170‐172	°C.	FT‐IR	(KBr,	,	
cm‐1):	 3390	 (NH),	 2920	 (Ar‐CH),	 2840	 (Aliph‐CH),	 1600													
(‐N=CH).	 1H	 NMR	 (300	 MHz,	 DMSO‐d6,	 δ,	 ppm):	 3.53	 (s,	 3H,							
‐OCH3),	6.87‐7.61	(m,	10H,	Ar‐H),	8.01	(s,	1H,	N=CH),	10.10	(s,	
1H,	NH).	Anal.	calcd.	for	C19H15N3OS	(333.41):	C,	68.45;	H,	4.53;	
N,	12.60.	Found:	C,	64.42;	H,	4.52;	N,	12.59%.	
	
2.7.	General	procedure	for	the	preparation	of	the	3‐(4‐1H‐
indol‐3‐yl)thiazol‐2‐yl)‐2‐(4‐substituted	phenyl)thiazolidin‐
4‐one	(6a‐c)	
	
A	 mixture	 of	 Schiff's	 base	 (5a‐c)	 (0.01	 mol)	 and	
thioglycolic	 acid	 (0.01	 mol)	 was	 refluxed	 in	 dimethyl	
formamide	(15	mL)	 for	6	h.	The	reaction	mixture	was	cooled	
and	poured	 into	 crushed	 ice.	 The	 solid	 obtained	was	 filtered	
and	 recrystallized	 from	 ethanol	 to	 give	 compounds	 6a‐c	
(Scheme	3).	
3‐(4‐(1H‐Indol‐3‐yl)thiazol‐2‐yl)‐2‐phenyl	 thiazolidin‐4‐one	
(6a):	 Color:	 Pale	 brown.	 Yield:	 82%.	M.p.:	 200‐204	 °C.	 FT‐IR	
(KBr,	,	cm‐1):	3225	(NH),	1700	(C=O),	1631(C=N),	1583	(C=C).	
1H	NMR	(300	MHz,	DMSO‐d6,	δ,	ppm):	4.00	(s,	2H,	COCH2S),	5.9	
(s,	1H,	‐NCHS),	6.6‐7.6	(m,	11H,	Ar‐H),	10.1	 (s,	1H,	NH).	Anal.	
calcd.	 for	 C20H15N3OS2:	 C,	 63.64;	 H,	 4.01;	 N,	 11.13.	 Found:	 C,	
63.62;	H,	4.00;	N,	11.10%.	
3‐(4‐(1H‐Indol‐3‐yl)thiazol‐2‐yl)‐2‐(4‐chlorophenyl)thiazo	
lidin‐4‐one	(6b):	Color:	Pale	brown.	Yield:	84%.	M.p.:	210‐212	
°C.	FT‐IR	(KBr,	,	cm‐1):	3300	(NH),	1700	(C=O),	1600	(‐N=C‐).	
1H	NMR	(300	MHz,	DMSO‐d6,	δ,	ppm):	3.83	(s,	2H,	COCH2S),	5.8	
(s,	1H,	‐NCHS),	7.1‐7.8	(m,	10H,	Ar‐H),	10.1	 (s,	1H,	NH).	Anal.	
calcd.	for	C20H14ClN3OS2:	C,	58.31;	H,	3.43;	N,	10.20.	Found:	C,	
58.29;	H,	3.40;	N,	10.19%.	
3‐(4‐(1H‐Indol‐3‐yl)thiazol‐2‐yl)‐2‐(4‐methoxyphenyl)thia	
zolidin‐4‐one	(6c):	Color:	Brown.	Yield:	84%.	M.p.:	205‐210	°C.	
FT‐IR	 (KBr,	,	 cm‐1):	 3290	 (NH),	 2920	 (Ar‐CH),	 2840	 (Aliph‐
CH),	1690	(C=O),	1600	(‐N=C).	1H	NMR	(300	MHz,	DMSO‐d6,	δ,	
ppm):	 3.4	 (s,	 2H,	 COCH2S),	 3.70	 (s,	 3H,	 ‐OCH3),	 5.90	 (s,	 1H,	
NCHS),	6.60‐7.90	(m,	10H,	Ar‐H),	10.10	(s,	1H,	NH).	Anal.	calcd.	
for	C21H17N3O2S2:	C,	61.89;	H,	4.20;	N,	10.31.	Found:	C,	61.88;	H,	
4.19;	N,	10.30%.	
	
2.8.	Synthesis	of	3‐(4‐(1H‐Indol‐3‐yl)thiazol‐2yl)‐5‐
benzylidiene‐2‐phenylthiazolidin‐4‐one	(7)	
	
A	mixture	of	compound	6a	(0.01	mole)	and	benzaldehyde	
(0.01	 mole)	 was	 refluxed	 in	 absolute	 ethanol	 (30	 mL)	 and	
catalyzed	 with	 few	 drops	 of	 TEA	 for	 5	 h.	 After	 cooling	 the	
obtained	 solid	was	 filtered,	 washed,	 dried	 and	 recrystallized	
from	ethanol	(Scheme	4).		Color:	Brown.	Yield:	89%.	M.p.:	220‐
222	 °C.	 FT‐IR	 (KBr,	,	 cm‐1):	 3420	 (NH),	 3040	 (Ar‐CH),	 1700	
(C=O),	1600	(C=C).	1H	NMR	(300	MHz,	DMSO‐d6,	δ,	ppm):	5.90	
(s,	 1H,	 NCHS),	 6.10	 (s,	 1H,	 ‐CH‐),	 7.10‐7.90	 (m,	 16H,	 Ar‐H),	
10.40	 (s,	 1H,	 NH).	 Anal.	 calcd.	 for	 C27H19N3OS2:	 C,	 69.65;	 H,	
4.11;	N,	9.03.	Found:	C,	69.64;	H,	4.10;	N,	9.04	%.	
	
2.9.	Synthesis	of	3‐(4‐(1H‐indol‐3‐yl)thiazol‐2‐yl)‐5‐amino‐
2,3‐dihydro‐2,7‐diphenylthiazolo[4,5‐b]pyridine‐6‐
carbonitrile	(8)	
	
A	mixture	of	compound	7	(0.01	mole),	malononitrile	(0.01	
mole)	and	ammonium	acetate	 (1	g)	 in	30	mL	acetic	acid	was	
refluxed	for	3	h.	The	solid	formed	upon	cooling	was	collected	
by	 filtration,	 washed	 with	 water	 and	 recrystallized	 from	
ethanol	(Scheme	4).	Color:	Pale	orange.	Yield:	72%.	M.p.:	256‐
258	°C.	FT‐IR	(KBr,	,	cm‐1):	3410,	3285	(NH,	NH2),	3040	(Ar‐
CH),2200	 (CN),	 1600	 (C=C).	 1H	 NMR	 (300	MHz,	 DMSO‐d6,	 δ,	
ppm):	4.00	(s,	2H,	NH2),	4.90	(s,	1H,	‐NCHS),	7.00‐7.90	(m,	16H,	
Ar‐H),	10.01	(s,	1H,	NH).	Anal.	 calcd.	 for	C30H20N6S2:	C,	68.16;	
H,	3.81;	N,	15.90.	Found:	C,	68.14;	H,	3.80;	N,	15.89%.	
	
2.10.	Synthesis	of	1‐(3‐(4‐(1H‐indol‐3‐yl)thiazol‐2‐yl)‐2,3‐
dihydro‐5‐methyl‐2,7‐Diphenylthiazolo[4,5‐b]pyridine‐6‐
yl)ethanone	(9)	
	
A	mixture	of	compound	7	(0.01	mole),	acetylacetone	(0.01	
mole)	and	ammonium	acetate	 (1	g)	 in	30	mL	acetic	acid	was	
refluxed	for	3	h.	The	solid	formed	upon	cooling	was	collected	
by	 filtration,	 washed	 with	 water	 and	 recrystallized	 from	
ethanol	(Scheme	4).	Color:	Pale	brown.	Yield:	64%.	M.p.:	200‐
204	 °C.	 FT‐IR	 (KBr,	,	 cm‐1):	 3410	 (NH),	 3040	 (Ar‐CH),	 2840	
(Aliph‐CH),1660	(CO),	1595	(C=C).	1H	NMR	(300	MHz,	DMSO‐
d6,	δ,	ppm):	3.20	(s,	3H,	COCH3),	3.80	(s,	3H,	‐N=C‐CH3),	4.95	(s,	
1H,	‐NCHS),	6.90‐7.90	(m,	16H,	Ar‐H),	10.20	(s,	1H,	NH).	Anal.	
calcd.	 for	 C32H24N4OS2:	 C,	 70.56;	 H,	 4.44;	 N,	 10.29.	 Found:	 C,	
70.50;	H,	4.41;	N,	10.27%.	
	
2.11.	Antimicrobial	activity	
	
Antimicrobial	 activity	 of	 the	 tested	 compounds	 was	
determined	 using	 a	 modified	 Kirby‐Bauer	 disc	 diffusion	
method	 [29].	 Briefly,	 100	 µL	 of	 the	 test	 bacteria/fungi	 were	
grown	 in	10	mL	of	 fresh	media	until	 they	 reached	a	 count	of	
approximately108	cells/mL	for	bacteria	105	cells/mL	for	fungi	
[30].		
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Table	1.	In‐vitro	antibacterial	and	antifungal	screening	of	the	newly	synthesized	compounds.	
Sample	 Inhibition	zone	diameter	(mm/mg	sample)	
Escherichia	coli	(G‐)	 Staphylococcus	aureus	(G+) Aspergillus	flavus	(Fungus) Candida	albicans	(Fungus)
1	 10	 9	 0.0 0.0	
2	 9	 0.0	 0.0 0.0	
3	 10	 11	 0.0 0.0	
6a	 10	 9	 0.0 0.0	
6b	 12	 16	 0.0 0.0	
6c	 10	 10	 0.0 0.0	
DMSO	 0.0	 0.0	 0.0 0.0	
Ampicillin	 22	 18	 0.0 0.0	
Amphotericin	B	 0.0	 0.0	 17 19	
	
	
 
	
Scheme	4
	
	
100	 µL	 of	 microbial	 suspension	 was	 spread	 onto	 agar	
plates	 corresponding	 to	 the	 broth	 in	 which	 they	 were	
maintained.	 Isolated	 colonies	of	 each	organism	 that	might	be	
playing	 a	 pathogenic	 role	 should	 be	 selected	 from	 primary	
agar	 plates	 and	 tested	 for	 susceptibility	 by	 disc	 diffusion	
method	 [31‐33].	 Of	 the	 many	 media	 available,	 National	
Committee	 for	 Clinical	 Laboratory	 Standards	 (NCCLS)	
recommends	 Mueller‐Hinton	 agar	 due	 to	 itsgood	 results	 in	
batch‐to‐batch	 reproducibility.	 Disc	 diffusion	 method	 for	
filamentous	 fungi	 tested	by	using	approved	standard	method	
(M38‐A)	[34]	for	evaluating	the	susceptibilities	of	filamentous	
fungi	 to	 antifungal	 agents.	 Disc	method	 for	 yeasts	 developed	
by	 using	 approved	 standard	 method	 (M44‐P)	 [35].	 Plates	
inoculated	with	filamentous	fungi	as	Aspergillus	flavus	at	25	°C	
for	48	h;	Gram	(+)	bacteria	as	Staphylococcus	aureus;	Gram	(‐)	
bacteria	 as	Escherichia	 coli,	 they	were	 incubated	 at	 35‐37	 °C	
for	24‐48	h	and	yeast	as	Candida	albicans	incubated	at	3	°C	for	
24‐48	h	and,	 then	 the	diameters	of	 the	 inhibition	zones	were	
measured	 in	 millimeters	 [27].	 Standard	 discs	 of	 Ampicillin	
(Antibacterial	 agent),	 Amphotericin	 B	 (Antifungal	 agent)	
served	as	positive	controls	for	antimicrobial	activity	but	filter	
discs	 impregnated	 with	 10	 µL	 of	 solvent	 (Distilled	 water,	
chloroform,	DMSO)	were	used	as	a	negative	control.	The	agar	
used	 is	 Meuller‐Hinton	 agar	 that	 is	 rigorously	 tested	 for	
composition	and	pH.	Furthermore,	the	depth	of	the	agar	in	the	
plate	is	a	factor	to	be	considered	in	the	disc	diffusion	method.	
This	 method	 is	 well	 documented	 and	 standard.	 A	 zone	 of	
inhibition	 has	 been	 determined	 for	 susceptible	 and	 resistant	
values.	Blank	paper	disks	(Schleicher	&	Schuell,	Spain)	with	a	
diameter	 of	 8.0	mm	were	 impregnated	with	 10	 µL	 of	 tested	
concentration	of	 the	stock	solutions.	When	a	 filter	paper	disc	
impregnated	 with	 a	 tested	 chemical	 is	 placed	 on	 agar	 the	
chemical	will	diffuse	from	the	disc	into	the	agar.	This	diffusion	
will	 place	 the	 chemical	 in	 the	 agar	 only	 around	 the	disc.	 The	
solubility	of	the	chemical	and	its	molecular	size	will	determine	
the	size	of	the	area	of	chemical	 infiltration	around	the	disc.	 If	
an	organism	is	placed	on	the	agar	it	will	not	grow	in	the	area	
around	the	disc	if	it	is	susceptible	to	the	chemical.	This	area	of	
no	growth	around	 the	disc	 is	 known	as	 a	 “Zone	of	 inhibition”	
or"	Clear	zone”.	For	the	disc	diffusion,	the	zone	diameters	were	
measured	with	slipping	calipers	of	the	National	Committee	for	
Clinical	Laboratory	Standards	 [31].	Agar‐based	methods	such	
as	 test	 and	 disk	 diffusion	 can	 be	 good	 alternatives	 because	
they	are	simpler	and	faster	than	broth‐based	methods	[35‐37]	
(Table	1).	
	
2.12.	Anticancer	activity	
	
2.12.1.	Cell	culture	
	
The	 cells	were	obtained	 from	Egyptian	Holding	Company	
for	Biological	Products	&	Vaccines	(VACSERA),	Giza,	Egypt	and	
then	 maintained	 in	 the	 tissue	 culture	 unit	 .The	 cells	 were	
grown	 in	 RBMI‐1640	medium,	 supplemented	with	 10%	 heat	
inactivated	 FBS,	 50	 units/mL	 of	 penicillin	 and	 50	mg/mL	 of	
streptomycin	 and	 maintained	 at	 [37]	 in	 a	 humidified	
atmosphere	containing	5%	CO2.	The	cells	were	maintained	as	
monolayer	 culture	 by	 serial	 sub‐culturing.	 Cell	 culture	
reagents	were	obtained	 from	Lonza	(Basel,	Switzerland).	The	
anticancer	 activity	 of	 the	 rested	 compounds	 was	 evaluated	
against	 MCF‐7	 cells	 (Breast	 cancer),	 HEPG‐2	 cells	 (Liver	
cancer)	and	HCT	116	(Colon	cancer)	(Table	2).	
	
2.12.2.	The	sulforhodamine	B	(SRB)	cytotoxicity	assay	
	
Cytotoxicity	was	 determined	 using	 the	 sulforhodamine	 B	
(SRB)	assay	method	as	previously	described	by	Skehan	et	al.	
[35].	Exponentially	 growing	 cells	were	 collected	using	0.25%	
Trypsin‐EDTA	 and	 seeded	 in	 96‐well	 plates	 at	 1000‐2000	
cells/well	 in	 RBMI‐1640	 supplemented	 medium.	 After	 24	 h,	
cells	were	 incubated	 for	 72	 h	with	 various	 concentrations	 of	
the	 tested	 compounds.	 Following	 72	 h	 treatments,	 the	 cells	
would	be	fixed	with	10%	trichloroacetic	acid	for	1	h	at	4	°C.		
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Table	2.	In‐vitro	anticancer	screening	of	the	newly	synthesized	compounds	against	different	cell	lines.	
Compound	 IC50	(µM)	
MCF‐7	(Breast	cancer)	 HEPG‐2	(Liver	cancer) HCT	116	(Colon	cancer)	
1	 20.35	 16.54	 14.91	
2	 73.87	 50.60	 45.48	
3	 19.23	 12.11 12.42
6a	 26.74	 14.15 16.44
	
	
Wells	 were	 stained	 for	 10	minutes	 at	 room	 temperature	
with	0.4%	SRBC	(Sulphorhodamine	B)	dissolved	 in	1%	acetic	
acid.	 The	 plates	 were	 air	 dried	 for	 24	 h	 and	 the	 dye	 was	
solubilized	with	Tris‐HCl	 for	5	min	on	a	 shaker	at	1600	rpm.	
The	 optical	 density	 (OD)	 of	 each	 well	 was	 measured	
spectrophotometrically	 at	 564	 nm	with	 an	 ELISA	microplate	
reader	 (ChroMate‐4300,	 FL,	 USA).	 The	 IC50	 values	 were	
calculated	 according	 to	 the	 equation	 for	 Boltzman	 sigmoidal	
concentration	 response	 curve	 using	 the	 nonlinear	 regression	
fitting	models	(Graph	Pad,	Prism	Version	5)	
	
3.	Results	and	discussion	
	
3.1.	Synthesis	
	
Our	 synthetic	 strategy	 for	 1,	 3‐thiazolidin‐4‐one	 deriva‐
tives	 starts	 with	 refluxing	 of	 3‐	 acetyl	 indol	 and	 thiourea	 in	
propanol	 to	 afforded	 4(1H‐indol‐3‐yl)	 thiazol‐2‐amine	 (1)	
which	 formed	 by	 the	 attack	 of	 sulphur	 nucleophile	 on	 imine	
carbon	 followed	by	 intermolecular	 cyclization	 on	 elimination	
of	water,	Scheme	1.	
Chloroacetamide	(2)	was	obtained	by	reacting	of	2‐amino	
thiazoles	 (1)	 with	 chloroacetyl	 chloride	 in	 presence	 of	
pyridine.	The	IR	of	compound	2	showed	the	presence	of	bands	
characteristic	 for	 C=N	 at	 1631‐1642	 cm‐1	 and	 an	 amide	
function	at	1661	(C=O)	and	3160‐3184	cm‐1	(NH).	The	1H	NMR	
of	 compound	 2	 revealed	 a	 broad	 singlet	 at	 δ	 10.32	 ppm	
characteristic	 for	 a	 secondary	 amine	 group,	 a	 multiplet	 at	 δ	
7.14‐7.55	ppm	for	aromatic	protons	and	COCH2	as	a	singlet	at	
δ	4.22	ppm.		
When	 chloroacetamide	 (2)	 was	 refluxed	 with	 potassium	
thiocyanate	in	dry	acetone,	2‐iminothiazolidine‐4‐one	(3)	was	
obtained	 in	 a	moderate	 to	 good	 yields.	 The	 structures	 of	 the	
isolated	 compounds	 were	 determined	 by	 spectral	 methods.	
The	IR	of	compound	3	revealed	characteristic	bands	for	C=N	at	
1602cm‐1,	C=O	at	1671cm‐1,	primary	and	secondary	amines	at	
3224‐3278cm‐1and	 3166‐3178	 cm‐1.	 The	 1H	 NMR	 spectra	
showed	the	presence	of	broad	exchangeable	singlets	at	δ	11.90	
ppm	NH	protons,	while	O=C‐CH2	protons	appears	at	δ	4.1,	4.3	
ppm	for	C=NH	and	the	aromatic	protons	of	compound	3appear	
as	a	multiplet	at	δ	7.12‐8.57	ppm.	
The	 iminothiazolidine‐4‐one	 (3)	 on	Knoevenagel	 conden‐
sation	with	different	substituted	aryl	aldehydes	in	presence	of	
sodium	acetate	as	a	base	 in	glacial	acetic	acid	afforded	the	3‐
(4‐(1‐indol‐3‐yl)thiazol‐2‐yl)‐	 5‐benzylidene‐2‐iminothiazoli	
dine‐4‐one	(4a‐c)	which	established	on	the	basis	of	IR,	1H	NMR	
spectra	did	not	only	show	the	absence	of	CH2	protons	at	δ	4.1	
ppm,	but	also	the	presence	of	HC=C	proton	at	δ	7.24‐7.37	ppm,	
Scheme	2.	
New	 compounds	 (5a‐c)were	 prepared	 by	 refluxing	 2‐
amino‐4‐aryl	thiazole	(1)	and	substituted	benzaldehyde,	a	few	
drops	of	glacial	acetic	acid	in	methanol	for	5‐6	h.	These	Schiff’s	
base	(5a‐c)	and	thioglycolic	acid	(0.01	mol)	when	refluxed	 in	
dimethyl	 formamide	 (15	 mL)	 for	 6	 h	 afforded	 the	 3‐(4‐1H‐
indol‐3‐yl)thiazol‐2‐yl)‐2‐(4‐substituted	 phenyl)thiazolidin‐4‐
one	(6a‐c)	in	good	yield	which	determined	by	IR	and	1H	NMR	
spectra.	IR	spectra	showed	the	characteristic	bands	for	C=N	at	
1630‐1600	cm‐1	and	 	amide	function	at	1690‐1700	(C=O)	and	
3255‐3300	cm‐1	(NH).	The	1H	NMR	of	showed	the	presence	of	
one	 broad	 exchangeable	 singlet	 at	 δ	 10.1	 ppm	 (NH),	 a	
multiplet	 at	 δ	 7.1‐7.8	 ppm	 (Ar‐H's),	 a	 singlet	 at	 δ	 5.8	 ppm	
(thiazolyl‐C5‐H),	 and	 a	 singlet	 at	 δ	 3.83	 ppm	 (O=C‐CH2),	
Scheme	3.	
Condensation	 of	 compound	 (6a)	 with	 benzaldehyde	
affords	 5‐benzylidenethiazolo	 derivatives	 (7),	 later,	 refluxing	
of	 compound	 7	 with	 malononitrile	 in	 the	 presence	 of	
ammonium	 acetate	 resulted	 in	 cycloaddition	 affording	
thiazolopyridine	 derivative	 (8)	 which	 showed	 IR	 spectra	 at	
3410,	 3285	 (NH,	 NH2)	 and	 2200	 cm‐1	 (CN).	 The	 1H	 NMR	
spectra	showed	the	presence	of	broad	exchangeable	singlets	at	
δ	10.01	ppm	NH	protons,	while	NCHS	protons	appears	at	δ	4.9	
ppm	and	the	aromatic	protons	appears	as	a	multiplet	at	δ	7.00‐
7.90	ppm.	
Also,	 thiazolopyridine	 derivative	 (9)	 was	 obtained	 by	
using	 acetylacetonein	 the	 same	 manner	 the	 structure	 was	
confirmed	by	1H	NMR	spectra	showed	signal	at	δ	3.20	ppm	for	
OCH3,	δ	3.80	ppm	for	‐N=C‐CH3,	δ	4.95	ppm	‐NCHS	and	singlets	
at	 δ	 10.20	 ppm	 for	 NH.	 The	 structure	 of	 all	 newly	 isolated	
compounds	 was	 fully	 confirmed	 by	 spectral	 and	 elemental	
analyses	methods,	Scheme	4.	
	
3.2.	Antibacterial	activity	
	
All	 the	 tested	 compounds	 have	 antibacterial	 activity	
against	 Gram	 negative	 (Escherichia	 coli)	 and	 Gram	 positive	
(Staphylococcus	 aureus),	 bacteria	 except	 compound	 2	 which	
had	antibacterial	activity	against	Gram	negative	bacteria	only.	
Compound	6b	showed	the	highest	antibacterial	activity.	All	the	
tested	 compounds	 had	 no	 antifungal	 activity	 against	
Aspergillus	 flavus	 and	 Candida	 albicans.	 The	 antibacterial	
activity	 of	 the	 newly	 synthesized	 compounds	 is	 due	 to	 the	
presence	of	thiazolidine	ring	[6,7].	
All	 the	 synthesized	 compounds	 were	 tested	 for	 in	 vitro	
anticancer	 activity	 using	 SRB	 cytotoxicity	 assay	method.	 The	
anticancer	screening	of	the	tested	compounds	revealed	that	all	
the	 synthesized	 compounds	 exhibited	 a	 significant	 cytotoxic	
activity	against	MCF‐7	Breast	cancer,	HEPG‐2	Liver	cancer	and	
HCT116	 Colon	 cancer	 cell	 lines	 in	 variable	 degrees.	 The	
anticancer	activity	of	these	newly	synthesized	compounds	may	
be	 due	 to	 the	 presence	 of	 indoles.	 Previous	 studies	 revealed	
that	indoles	possess	a	high	anticancer	activity	against	different	
cell	lines	[19].	
From	Table	 2,	 we	 can	 notice	 that	 compound	3	 exhibited	
the	 most	 potent	 anticancer	 activity	 against	 MCF‐7	 Breast	
cancer,	 HEPG‐2	 Liver	 cancer	 and	 HCT116	 Colon	 cancer	 cell	
lines	 by	 IC50	 19.23,	 12.11	 and	 12.42	 µM,	 respectively,	 while	
compound	2	showed	the	least	anticancer	activity.	
	
4.	Conclusion	
	
Our	 present	 investigation	 is	 centered	 on	 the	 studies	 of	
synthesis,	 reactions,	spectral	analysis	and	biological	activities	
of	 1,3‐thiazolidin‐4‐ones	 derivatives.	 The	 procedure	 proved	
more	 beneficial	 than	 those	 previously	 reported	 in	 the	
literature.	Compound	3	exhibited	the	most	potent	antibacterial	
and	 anticancer	 activity.	All	 the	 compounds	had	no	 antifungal	
activity	against	Aspergillus	flavus	and	Candida	albicans.	
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